UNSPSC 51111624: Ancitabine

This classification denotes a pyrimidine antagonist with the molecular formula C9H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DO2D32W0VC, chemically known as 2,2-o-cyclocytidine but generally known as ancitabine, which bears US NIH Compound Identifier 25051. Ancitabine most often comes in base and hydrochloride forms. European Medicines Agency schedules Ancitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05507MIG.

UNSPSC 51111624 Ancitabine, a Commodity code, addresses pharmaceutical procurement by state and local health agencies. State and local governments buy ancitabine—a nucleoside analog used in cancer chemotherapy—through their Medicaid programs, employee health plans, and public health systems. The Texas Health and Human Services Commission is exploring restructured procurement models through direct manufacturer relationships rather than traditional pharmacy benefit manager channels, signaling a shift in how states source specialty pharmaceuticals. Ancitabine sourcing involves coordination with state pharmacy benefit programs, correctional health systems, and public hospital networks that manage inventory for eligible patients. Issuing bodies under this code are primarily state health and human services departments managing Medicaid formularies and pharmacy benefit administration, alongside county health systems and specialty treatment centers that dispense the drug.

Recent activity centers on Texas, where the HHS Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This exploratory RFI solicits information from vendors on their capacity to enter direct contracts with self-insured health plans and state agencies outside conventional pharmacy benefit manager and group purchasing organization arrangements, including experience with negotiated net pricing models and value-based agreements. The RFI represents preliminary market intelligence to inform the state's future procurement strategy before issuing a formal RFP; no award values, budget ranges, or specific response requirements beyond vendor capability data are specified at this stage. Geographic activity remains limited to the posted opportunity; the source does not support identification of activity in other states or jurisdictions under this code during the recent period.